International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1222-1230 , 15 November 2007

Enhanced Response of Human Head and Neck Cancer Xenograft Tumors to Cisplatin Combined With 2-Deoxy-d-Glucose Correlates With Increased 18F-FDG Uptake as Determined by PET Imaging

  • Andrean L. Simons, Ph.D.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Melissa A. Fath, R.Ph., Ph.D.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • David M. Mattson, M.D.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Brian J. Smith, Ph.D.

      Affiliations

    • Department of Biostatistics, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Susan A. Walsh, M.A.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Michael M. Graham, M.D., Ph.D.

      Affiliations

    • Department of Radiology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Richard D. Hichwa, Ph.D.

      Affiliations

    • Department of Radiology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • John M. Buatti, M.D.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Ken Dornfeld, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • ,
  • Douglas R. Spitz, Ph.D.

      Affiliations

    • Department of Radiation Oncology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
    • Corresponding Author InformationReprint requests to: Douglas R. Spitz, Ph.D., Free Radical and Radiation Biology Program, Department of Radiation Oncology, B180 Medical Laboratories, University of Iowa, Iowa City, IA 52242. Tel: (319) 335-8019; Fax: (319) 335-8039

Received 22 May 2007 ,Revised 5 July 2007 ,Accepted 6 July 2007.

References 

  1. Caravalho AL, Nishimoto IN, Caifano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–816
  2. Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol. 1994;21:20–27
  3. Bourhis J, Le Maitre A, Baujat B, et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol. 2007;19:188–194
  4. Marcu L, van Doorn T, Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer. Acta Oncol. 2003;42:315–325
  5. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  6. Zackrisson B, Mercke C, Strander H, et al. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 2003;42:443–461
  7. Dornfeld K, Simmons JR, Karnell L, et al. Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life. Int J Radiat Oncol Biol Phys. 2007;68:750–757
  8. El-Deiry M, Funk GF, Nalwa S, et al. Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2005;131:879–885
  9. Warburg O. On the origin of cancer cells. Science. 1956;132:309–314
  10. Spitz DR, Sim JE, Ridnour LA, et al. Glucose deprivation-induced oxidative stress in human tumor cells: A fundamental defect in metabolism?. Ann NY Acad Sci. 2000;899:349–362
  11. Andringa KK, Coleman MC, Aykin-Burns N, et al. Inhibition of glutamate cysteine ligase (GCL) activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-d-glucose. Cancer Res. 2006;66:1605–1610
  12. Lin X, Zhang F, Bradbury CM, et al. 2-Deoxy-d-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res. 2003;63:3413–3417
  13. Simons AL, Ahmad IM, Mattson DM, et al. 2-Deoxy-d-glucose (2DG) combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67:3364–3370
  14. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1991;179:765–770
  15. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg. 2002;236:208–217
  16. Schwartz DL, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003;129:1173–1178
  17. Yao M, Graham M, Smith R, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report. Int J Radiat Oncol Biol Phys. 2004;60:1410–1418
  18. Dobert N, Kovacs AF, Menzel C, et al. The prognostic value of FDG PET in head and neck cancer. Correlation with histopathology. J Nucl Med Mol Imaging. 2005;49:253–257
  19. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130:1361–1367
  20. Anderson ME. Handbook of methods for oxygen radical research. Florida: CRC; 1985;p. 317–323
  21. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem. 1980;106:207–212
  22. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–275
  23. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22
  24. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  25. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol. 1997;43:29–37
  26. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18:1458–1464
  27. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36:999–1004
  28. Taylor SG, Murthy AK, Griem KL, et al. Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-Year analysis of results. Head Neck. 1997;19:684–691
  29. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004;22:2856–2864
  30. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072–1078
  31. Halicka HD, Ardelt B, Li X, et al. 2-Deoxy-d-glucose enhances sensitivity of human histiocytic lymphoma U937 cells to apoptosis induced by tumor necrosis factor. Cancer Res. 1995;55:444–449
  32. Dwarakanath BS, Khaitan D, Ravindranath T. 2-Deoxy-d-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines. Cancer Biol Ther. 2004;3:864–870
  33. Jeremic B, Milicic B, Dagovic A, et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2004;22:3540–3548
  34. Stokkel MPM, ten Broek FW, van Rijk PP. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol. 1998;34:466–471
  35. Kitagawa Y, Nishizawa S, Sano K, et al. FDG-PET for the prediction of tumor aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med. 2003;30:63–71

 Supported by: NIH RO1-CA100045 (D.R.S.), NIH P01-CA66081 (A.L.S.), NIH P30-CA086862 (B.J.S., M.M.G., R.D.H., D.R.S.), T32 CA078586-08 (M.A.F., A.L.S.), RSNA HPSD0602 (D.M.M.), and the Department of Radiation Oncology at the University of Iowa (D.M.M., K.D., J.M.B.).

 Conflict of interest: none.

PII: S0360-3016(07)03693-0

doi: 10.1016/j.ijrobp.2007.07.2343

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1222-1230 , 15 November 2007

Article Tools

* Image Usage & Resolution